CGON
CG Oncology, Inc.
$69.20
-0.06 (-0.09%)
At close · Jul 7
Market Cap
$6.10B
Shares
88,202,473
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$69.20
Open$69.75
Day$67.93–70.39
52W$23.65–76.60
Avg vol 30d1.0M
Short int10.6M · 12.0% float · 11.6d
Short vol62%
Last earningsMay 8, 2026
DataJan 2024–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+28%
above
Price vs 50-day avg
+7%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
86%
near high
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+29%
trailing
YTD return
+67%
this year
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $65 › 200d $54 — 50d above 200d
Institutional flow
Distributing
5 of 237 funds reported for Jun 30 · net -56 sh shares
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
11.97% of float · ▲ +7.6% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
237 holders — near 2-yr high, broad support
Squeeze score
89
high risk · 0–100
Fundamentals
EPS growth
−48%
Y/Y
Free cash flow
$-132.5M
Balance sheet
$32.5M
net cash
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+28%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
86%
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $65 › 200d $54 — 50d above 200d
Institutional flow
Distributing
5 of 237 funds reported for Jun 30 · net -56 sh shares
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
11.97% of float · ▲ +7.6% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
237 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $24
Now $69 · 86%
52-wk high $77
vs 200-day avg +28%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGON
this stock
CG Oncology, Inc.
|
$6.10B | +66.7% | — | — | 12.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGON | -5.4% | +28.8% | +28.8% | -2.6% | +66.7% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -6.3% | +27.4% | +21.3% | -2.7% | +57.0% |